We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
The TAXIT study by KU Leuven demonstrated the positive effect of the therapeutic drug monitoring of infliximab with regards to cost savings and therapy optimisation. R-Biopharm develops products and processes to optimise TDM.